{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:09Z","timestamp":1786118889053,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1097\/jcp.0b013e3181730850","type":"journal-article","created":{"date-parts":[[2008,5,9]],"date-time":"2008-05-09T03:06:01Z","timestamp":1210302361000},"page":"325-328","source":"Crossref","is-referenced-by-count":9,"title":["Concentration-Response Relationship for Fluvoxamine Using Remission as an Endpoint"],"prefix":"10.1097","volume":"28","author":[{"given":"Yutaro","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Sawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Sugai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vural","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Someya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210128","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00007691-200004000-00001","article-title":"Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of selective serotonin reuptake inhibitor?","volume":"22","author":"Rasmussen","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R2-11-20210128","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archpsyc.1992.01820100005001","article-title":"Treatments of depression and the functional capacity to work.","volume":"49","author":"Mintz","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"R3-11-20210128","first-page":"157","article-title":"Predictors of placebo response: a retrospective analysis.","volume":"28","author":"Wilcox","year":"1992","journal-title":"Psychopharmacol Bull"},{"key":"R4-11-20210128","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0165-1781(92)90002-K","article-title":"Clinical features of depressed patients who do and do not improve with placebo.","volume":"41","author":"Brown","year":"1992","journal-title":"Psychiatry Res"},{"key":"R5-11-20210128","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.tpj.6500256","article-title":"The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients.","volume":"4","author":"Suzuki","year":"2004","journal-title":"Pharmacogenomics J"},{"key":"R6-11-20210128","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1017\/S1461145704004687","article-title":"The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings.","volume":"7","author":"Serretti","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"R7-11-20210128","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-2007-979327","article-title":"Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial.","volume":"31","author":"Hartter","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"R8-11-20210128","first-page":"367","article-title":"The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine.","volume":"51","author":"Nathan","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"R9-11-20210128","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00213-003-1430-1","article-title":"Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.","volume":"167","author":"Gerstenberg","year":"2003","journal-title":"Psychopharmacology"},{"key":"R10-11-20210128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0165-0327(82)90009-X","article-title":"Fluvoxamine and clomipramine in endogenous depression.","volume":"4","author":"De Wilde","year":"1982","journal-title":"J Affect Disord"},{"key":"R11-11-20210128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0924-977X(93)90290-3","article-title":"Plasma concentration of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects.","volume":"3","author":"Kasper","year":"1993","journal-title":"Eur Neuropsychopharmacol"},{"issue":"suppl 4","key":"R12-11-20210128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1359786806066044","article-title":"Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies.","volume":"20","author":"Lotrich","year":"2006","journal-title":"J Psychopharmacol"},{"key":"R13-11-20210128","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/archpsyc.60.4.386","article-title":"High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography.","volume":"60","author":"Suhara","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R14-11-20210128","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00406-005-0579-5","article-title":"Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed?","volume":"255","author":"Adli","year":"2005","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R15-11-20210128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/da.10076","article-title":"Is there a SSRI dose response in treating major depression? The case for re-analysis of current data and for enhancing future study design.","volume":"17","author":"Baker","year":"2003","journal-title":"Depress Anxiety"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/JCP.0b013e3181730850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:01:56Z","timestamp":1786035716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-200806000-00011"}},"subtitle":["A Receiver Operating Characteristics Curve Analysis in Major Depression"],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181730850","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}